Pfizer (NYSE:PFE) has been dismissed as a defendant in a major federal lawsuit alleging generic drug price fixing. The court ...
The National Healthcare Security Administration said on Monday that 557 drugs have passed the preliminary review for ...
Demand for GLP-1 drugs such as semaglutide is exposing capacity gaps across peptide APIs, sterile fill-finish facilities, ...
Kriya Therapeutics, Inc. ("Kriya"), a biotechnology company developing durable medicines for chronic diseases, today announced it has been selected by the U.S. Food and Drug Administration (FDA) to ...
As drug costs and spending continue to rise, the demand for solutions opens the door to closer collaboration between payers ...
FDA takes an industry-friendly approach; Trump aide in consideration to lead FDA; Biotech CEOs are suddenly bullish.
The Print on MSN
How can India go from manufacturing medicines to discovering them—funding is a key
While multinational pharmaceutical companies use India to test out their new medicines, India’s researchers rarely lead the ...
Dr Reddy's whitepaper says weak translational research ecosystem is slowing the journey from laboratory breakthroughs to ...
M upfront, up to $1.8B milestones, and what it signals for NVS amid patent cliffs. Click for this look at the deal.
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has ...
Teplizumab is an immunotherapy drug designed to modify the immune system's response. Instead of simply treating symptoms, it ...
Teplizumab is an immunotherapy drug designed to modify the immune system's response. Instead of simply treating symptoms, it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results